The clinical safety of the split influenza vaccine Anflu in adults and elders
10.3321/j.issn:0253-9624.2008.z1.030
- VernacularTitle:流行性感冒裂解疫苗安尔来福在成人和老年人中应用的安全性观察
- Author:
Er-Ke YOU
1
;
Xiang XIONG
;
Jin-Yue PENG
;
Fu-Ying LIU
;
Wei-Qiu NAN
;
Li-Ping MA
;
Mao-Lin PENG
;
Yan LIU
;
XU WANG
Author Information
1. 湖北省十堰市东风疾病预防控制所
- Keywords:
Influenza vaccine;
Safety;
Evaluation studies
- From:
Chinese Journal of Preventive Medicine
2008;42(z1):135-137
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety of the split influenza vaccine Anflu.Methods A total of 198 subjects were enrolled in this open clinical trial.Of which,97 aged 18-60 years old and 101 aged 61 years old.28 of the subjects had history of chronic disease,while all the subjects were under stable health condition.After being infoma consented,each subject was vaccinated with one dose of split influeza vaccine and observed for 7 days for adverse reactions.Results A total of 17 subjects reported adverse reactions and the adverse reactions occurrence rate was 8.6%.The adverse reactions occurrence rate was 13.4%in the adult group and 4.0%in the elderly group(x2=5.620,P=0.018).Local adverse reactions occurrence rate was 5.5%and pain at the iniection site was the major symptom.System adverse reactions rate was 3.5% and fever was the most frequently reported symptom.None of the subjects with chronic disease history reported adverse reactions.Conclusion The results showed that the vaccine did not cause new adverse reaction,serious adverse event or rare adverse reaction.The split influenza vaccine was safe.
